Senti Biosciences Inc.
09/27/2024 | Press release | Distributed by Public on 09/27/2024 14:43
Material Agreement Form 8 K
Item 1.01 Entry into a Material Definitive Agreement.
On September 23, 2024, Senti Biosciences, Inc. (the "Company"), as the sublandlord, entered into a sublease agreement, or the Sublease, with BKPBIOTECH, Inc., a Delaware corporation and JLSA2 Therapeutics, Inc., a Delaware corporation (jointly and severally, the "Subtenant") for approximately 7,247 rentable square feet (the "RSF") of certain space located on a portion of the first floor of the Company's corporate headquarters, Two Corporate Drive, First Floor, South San Francisco, CA 94080. The term of the Sublease is estimated to be effective on October 1, 2024, subject to the consent by the landlord, Britannia Biotech Gateway Limited Partnership and will expire April 30, 2027, subject to earlier termination in accordance with the terms of the Sublease. The initial monthly base rent the Subtenant will pay is $35,147.95 per month for the first year of the sublease term, increasing to $36,378.13 per month for the second year of the sublease term, and increasing to $37,651.36 per month for the third year of the sublease term. The Sublease contains customary events of default, representations, warranties and covenants.
The foregoing description of the Sublease does not purport to be a complete description of the rights and obligations of the parties thereunder, and is qualified in its entirety by reference to the full text of the Sublease, which the Company expects to file as an exhibit to its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2024.